Visionary Physicist's Crusade Serves As Lesson In Futility

PRINCETON, NJ.—Drop a certain name in conversation with a fusion scientist or a Department of Energy official and you’re likely to observe an unusual reaction. Rolling eyes and sighs are common responses; mild cases of apoplexy are not unknown. Usually composed researchers become animated, others simply nod their heads knowingly. Rarely does the name pass without comment. The name is Bogdan Maglich, and the man who owns it claims he’s just a scientist with a relatively mo

Written byRobert Crease
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

PRINCETON, NJ.—Drop a certain name in conversation with a fusion scientist or a Department of Energy official and you’re likely to observe an unusual reaction. Rolling eyes and sighs are common responses; mild cases of apoplexy are not unknown. Usually composed researchers become animated, others simply nod their heads knowingly. Rarely does the name pass without comment.

The name is Bogdan Maglich, and the man who owns it claims he’s just a scientist with a relatively modest request: He’d like $2 million with which to build a fusion device smaller than a cubic centimeter, with an output of one kilowatt and practically no radioactivity. He calls it a “migma,” and he says that hundreds of migmas can be strung together to form enormous power plants.

Maglich is sure it will work. So sure, in fact, that he has formed a company, Advanced Physics Corp., to promote the idea. Its board ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies